IP Library Granted Patent US 12667540
Granted Patent B2
US 12667540 · App. 18/282,365 · Granted Jun 30, 2026

Rolled oral thin films having a high level of active-ingredient loading

Inventors: Markus Müller (Troisdorf, DE); Christoph Schmitz (Rheinbrohl, DE); Michael Linn (Waldböckelheim, DE)
Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
A61K9/006A61K45/06A61K47/10A61K47/22A61K47/26A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667540
App. No.
18/282,365
Granted
Jun 30, 2026
Kind
B2
Abstract

The present invention relates to a method for producing a water-erodible, water-soluble or water-dispersible active-ingredient-administering form, in which, firstly, a film suitable as an oral film-administering form is produced which contains the active ingredient and in which a surface of the film is activated in a subsequent step in order to generate a tacky surface, followed by rolling up the activated film to form a rolled-up laminate. The present invention also relates to rolled-up laminates produced according to this method. Corresponding laminates are very stable, such that they can be dispensed and cut, and are suitable on account of their area density, which is very high by comparison with conventional OTF products, for administering active ingredients which have to be given in larger amounts.

Claims (21)

1 . A method for producing a water-soluble or water-dispersible active-ingredient-administering form comprising

(a) producing a film, suitable as oral film-administering form, having a content of active ingredient, wherein the film-administering form is present as a solid foam,

(b) activating a surface of the film produced in (a) in order to generate a tacky surface, and

(c) rolling up the film activated in (b) to form a rolled-up laminate.

2 . The method according to claim 1 , characterised in that the surface is activated and a tacky surface is generated by swelling, etching or melting of the surface.

3 . The method according to claim 1 , characterised in that the surface is activated and a tacky surface is generated by applying a self-adhering layer, wherein the self-adhering layer is formed from a water-erodible material and preferably a water-soluble or water-dispersible material.

4 . The method according to claim 1 , characterised in that the film suitable as an oral film-administering film is based on a film-forming polymer, selected from polyvinyl alcohol, polyethylene glycol, polyethylene oxide, cellulose derivatives, pullulan, gelatines, and agar.

5 . The method according to claim 4 , characterised in that the film-forming polymer accounts for a proportion of from 25 to 85 wt. % in the film.

6 . The method according to claim 1 , characterised in that the film suitable as oral film-administering form contains at least one excipient selected from flavourings or aromatic substances, colouring agents, plasticisers and sweeteners.

7 . The method according to claim 1 , characterised in that the active ingredient is an active pharmaceutical ingredient selected from the group comprising acetaminophen, adrenaline, alprazolam, amlodipine, anastrozole, apomorphine, aripiprazole, atorvastatin, baclofen, benzocaine, benzocaine/menthol, benzydamine, buprenorphine, buprenorphine/naloxone, buprenorphine/naloxone/cetirizine, cetirizine, chlorpheniramine, clomipramine, dexamethasone, dextromethorphan, dextromethorphan/phenylephrine, diclofenac, diphenhydramine, diphenhydramine/phenylephrine, donepezil, dronabinol, epinephrine, escitalopram, famotidine, fentanyl, glimepiride, GLP-1 peptides, granisetron, insulin, insulin nanoparticles, insulin/GLP-1 nanoparticles, ketamine, ketoprofen, ketotifen, caffeine, levocetirizine, loperamide, loratadine, meclizine, methylphenidate, midazolam, mirodenafil, montelukast, multimeric-001, naloxone, nicotine, nitroglycerin, olanzapine, olopatadine, ondansetron, oxybutynin, pectin, pectin/menthol, pectin/ascorbic acid, PediaSUNAT (artesunate and amodiaquine), piroxicam, phenylephrine, prednisolone, pseudoephedrine, risperidone, rivastigmine, rizatriptan, selegiline, Senna glycosides, sildenafil citrate, simethicone, sumatriptan, tadalafil, testosterone, triamcinolone acetonide, triptan, tropicamide, voglibose, zolmitriptan, zolpidem, or pharmaceutically acceptable salts of these compounds.

8 . The method according to claim 3 , characterised in that the self-adhering layer is based on a water-soluble or water-dispersible polymer.

9 . The method according to claim 8 , characterised in that the water-soluble or water-dispersible polymer accounts for a proportion of from 50 to 90 wt. % in the self-adhering layer.

10 . The method according to claim 1 , characterised in that the film suitable as oral film-administering form or the self-adhering film contains a plasticiser and/or a humectant.

11 . A rolled-up laminate, producible by a method according to claim 1 .

12 . The rolled-up laminate according to claim 11 , characterised in that it has a weight of from 100 to 1000 mg.

13 . The method according to claim 1 , characterised in that the film suitable as an oral film-administering film is based on polyvinyl alcohol.

14 . The method according to claim 4 , characterised in that the film-forming polymer accounts for a proportion of from 60 to 80 wt. % in the film.

15 . The method according to claim 3 , characterised in that the self-adhering layer is based on polyvinylpyrrolidone.

16 . The method according to claim 8 , characterised in that the water-soluble or water-dispersible polymer accounts for a proportion of from 60 to 85 wt. % in the self-adhering layer.

17 . The method according to claim 1 , characterised in that the film suitable as oral film-administering form or the self-adhering film contains a glycerol.

18 . The rolled-up laminate according to claim 11 , characterised in that it has a weight of from 200 to 800 mg.